



CCM DUOPHARMA BIOTECH BERHAD (524271-W)
(Incorporated in Malaysia)
UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE PERIOD ENDED 30 SEPT 2016

Group	Reserves					Retained Profit RM '000	Total RM '000
	Share Capital RM '000	Treasury Shares RM' 000	Non-distributable		Distributable		
			Share Premium RM '000	Revaluation Surplus RM '000	Translation Reserve RM '000		
At 1 January 2016	139,478	-	194,205	0	(722)	116,757	449,718
Foreign exchange translation differences					692		692
Total other comprehensive income for the period	-	-	-	-	692	-	692
Profit for the year						17,995	17,995
Total comprehensive income for the period	-	-	-	-	692	17,995	18,687
2015 final dividend (5.5 sen per share tax exempt)						(15,343)	(15,343)
At 30 Sept 2016	139,478	0	194,205	0	(30)	119,409	453,062



CCM DUOPHARMA BIOTECH BERHAD (524271-W)
(Incorporated in Malaysia)
UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE PERIOD ENDED 30 SEPT 2016

Group	Reserves					Retained Profit RM '000	Total RM '000
	Share Capital RM '000	Treasury Shares RM' 000	Share Premium RM '000	Revaluation Surplus RM '000	Translation Reserve RM '000		
At 1 January 2015	69,739	(1,578)	13,720	-	-	111,749	193,630
Foreign currency translation differences for foreign operations	-	-	-	-	(722)	-	(722)
Total comprehensive income for the period	-	-	-	-	-	36,391	36,391
Total comprehensive income for the period	69,739	(1,578)	13,720	-	(722)	148,140	229,299
Re-issuance of all treasury shares in open market		1,578	594				2,172
Distribution cost on reissuance of all treasury share in open market			(8)				(8)
2014 final dividend (14.5 sen per share tax exempt under single tier system)						(20,225)	(20,225)
2015 interim dividend (4 sen per share tax exempt under single tier system)						(11,158)	(11,158)
Issuance of ordinary shares pursuant to Right Issue exercise	69,739		181,324				251,063
Distribution cost pursuant to Right Issue exercise (net of tax)			(1,425)				(1,425)
At 31 December 2015	139,478	0	194,205	0	(722)	116,757	449,718

(The Condensed Consolidated Statement of Changes in Equity should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2015 and the accompanying explanatory notes attached to the interim financial statements.)



CCM DUOPHARMA BIOTECH BERHAD (524271-W)
(Incorporated in Malaysia)
UNAUDITED CONDENSED CONSOLIDATED CASH FLOW STATEMENT
FOR THE PERIOD ENDED 30 SEPT 2016

	30 Sept 2016	30 Sept 2015
	RM '000	RM '000
Cash flows from operating activities		
Profit before taxation	25,180	32,226
Adjustments for:		
Depreciation of property, plant and equipment	16,701	15,928
Interest income	(3,342)	(764)
Finance costs	4,109	2,301
Negative goodwill	-	(706)
<i>Operating profit before changes in working capital</i>	42,648	48,985
Change in inventories	(19,250)	(14,925)
Change in receivables, deposits and prepayments	(16,144)	62,676
Change in payables and accruals	26,591	(165,366)
Changes in provision	-	(84)
<i>Cash generated from operations</i>	33,845	(68,714)
Finance costs paid	(4,109)	(2,301)
Interest income	3,342	764
Income tax paid	(7,279)	(4,776)
Net cash generated from operating activities	25,799	(75,027)
Cash flows from investing activities		
Acquisition of property, plant and equipment	(16,640)	(26,353)
Acquisition of subsidiary, net of cash and cash equivalents acquired	-	(111,599)
Proceed from issuance of shares	-	253,228
Net cash used in investing activities	(16,640)	115,276
Cash flows from financing activities		
Drawdown of borrowings	5,000	245,490
Repayment of borrowings	(10,000)	(141,020)
Dividends paid to shareholders of the Company	(15,343)	(20,225)
Net cash used in financing activities	(20,343)	84,245
Net decrease in cash and cash equivalents	(11,184)	124,494
Cash and cash equivalents at 1 January	143,510	18,303
Cash and cash equivalents as at 30 Sept	132,326	142,797
	-	-
(l) Cash and cash equivalents comprise:		
	RM '000	RM '000
Cash and bank balances	32,387	29,082
Deposits placed with licensed financial institutions	99,939	113,715
	132,326	142,797

(The Condensed Consolidated Cash Flow Statement should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2015 and the accompanying explanatory notes attached to the interim financial statements.)